Skip to main content
SpringerLink
Log in

Osteopontin (Spp1)

  • Reference work entry
  • First Online:
Encyclopedia of Signaling Molecules

Synonyms

Bone sialoprotein 1; BNSP; BSPI; Early T-lymphocyte activation 1; ETA-1; Nephropontin; OPN; Osteopontin; Osteopontin-C; Osteopontin-D; Osteopontin/immunoglobulin alpha 1 heavy chain constant region fusion protein; PSEC0156; SPP-1; Secreted phosphoprotein 1; Secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, early T-lymphocyte activation 1); SPP1; SPP1/CALPHA1 fusion; Urinary stone protein; Uropontin

Historical Background

The protein product of gene Spp1 is known by many names; however, osteopontin (OPN) is the most widely used and preferred. Osteopontin was first identified in osteoblasts and is primarily known for its role in bone mineralization, hence derives the name “osteo” for bone and pontin from “pons”- bridge in Latin. Orthologous gene analysis of Spp1 gene indicates that it is found in 39 eukaryotic genera. In humans, OPN is expressed in many organs and plays an important role in many cellular, physiological, immunological, and pathological processes; thus,...

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 4,499.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 4,499.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Anborgh PH, Mutrie JC, Tuck AB, Chambers AF. Pre- and post-translational regulation of osteopontin in cancer. J of Cell Commun Signal. 2011;5:111–22. doi:10.1007/s12079-011-0130-6.

    Article  Google Scholar 

  • Beausoleil MS, Schulze EB, Goodale D, Postenka CO, Allan AL. Deletion of the thrombin cleavage domain of osteopontin mediates breast cancer cell adhesion, proteolytic activity, tumorgenicity, and metastasis. BMC Cancer. 2011;11. doi:10.1186/1471-2407-11-25.

    Google Scholar 

  • Bhattacharya SD, Mi Z, Kim VM, Guo H, Talbot LJ, Kuo PC. Osteopontin regulates epithelial mesenchymal transition-associated growth of hepatocellular cancer in a mouse xenograft model. Ann Surg. 2012;255:319–25. doi:10.1097/SLA.0b013e31823e3a1c.

    Article  PubMed  Google Scholar 

  • Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–7. doi:10.1038/nature01322.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Das S, Samant RS, Shevde LA. Nonclassical activation of Hedgehog signaling enhances multidrug resistance and makes cancer cells refractory to smoothened-targeting Hedgehog inhibition. J Biol Chem. 2013;288:11824–33. doi:10.1074/jbc.M112.432302.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Denhardt DT, Noda M, O’Regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Investig. 2001;107:1055–61. doi:10.1172/jci12980.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Fisher LW. DMP1 and DSPP: evidence for duplication and convergent evolution of two SIBLING proteins. Cells Tissues Organs. 2011;194:113–8. doi:10.1159/000324254.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Florea A-M, Büsselberg D. Breast cancer and possible mechanisms of therapy resistance. J Local Global Health. 2013;2. doi:10.5339/jlghs.2013.2.

    Google Scholar 

  • Franzen A, Heinegard D. Isolation and characterization of two sialoproteins present only in bone calcified matrix. Biochem J. 1985;232:715–24.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Heerboth S, Housman G, Leary M, Longacre M, Byler S, Lapinska K, et al. EMT and tumor metastasis. Clin Transl Med. 2015;4. doi:10.1186/s40169-015-0048-3.

    Google Scholar 

  • Ibrahim T, Leong I, Sanchez-Sweatman O, Khokha R, Sodek J, Tenenbaum HC, et al. Expression of bone sialoprotein and osteopontin in breast cancer bone metastases. Clin Exp Metastasis. 2000;18:253–60.

    Article  PubMed  CAS  Google Scholar 

  • Inoue M, Shinohara ML. Intracellular osteopontin (iOPN) and immunity. Immunol Res. 2011;49:160–72. doi:10.1007/s12026-010-8179-5.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Investig. 2009;119:1420–8. doi:10.1172/jci39104.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Kariya Y, Kanno M, Matsumoto-Morita K, Konno M, Yamaguchi Y, Hashimoto Y. OsteopontinO-glycosylation contributes to its phosphorylation and cell-adhesion properties. Biochem J. 2014;463:93–102. doi:10.1042/bj20140060.

    Article  PubMed  CAS  Google Scholar 

  • Katagiri YU, Murakami M, Mori K, Iizuka J, Hara T, Tanaka K, et al. Non-RGD domains of osteopontin promote cell adhesion without involving alpha v integrins. J Cell Biochem. 1996;62:123–31. doi:10.1002/(SICI)1097-4644(199607)62:1<123::AID-JCB13>3.0.CO;2-O.

    Article  PubMed  CAS  Google Scholar 

  • Kothari A, Arffa M, Chang V, Blackwell R, Syn W-K, Zhang J, et al. Osteopontin – a master regulator of epithelial-mesenchymal transition. J Clin Med. 2016;5:39. doi:10.3390/jcm5040039.

    Article  CAS  PubMed Central  Google Scholar 

  • Kurzbach D, Platzer G, Schwarz TC, Henen MA, Konrat R, Hinderberger D. Cooperative unfolding of compact conformations of the intrinsically disordered protein osteopontin. Biochemistry. 2013;52:5167–75. doi:10.1021/bi400502c.

    Article  PubMed  CAS  Google Scholar 

  • Kyprianou N, Huang J, Pan C, Hu H, Zheng S, Ding L. Osteopontin-enhanced hepatic metastasis of colorectal cancer cells. PLoS One. 2012;7:e47901. doi:10.1371/journal.pone.0047901.

    Article  CAS  Google Scholar 

  • Larue L, Bellacosa A. Epithelial–mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene. 2005;24:7443–54. doi:10.1038/sj.onc.1209091.

    Article  PubMed  CAS  Google Scholar 

  • Liaw L, Almeida M, Hart CE, Schwartz SM, Giachelli CM. Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. Circ Res. 1994;74:214–24.

    Article  PubMed  CAS  Google Scholar 

  • Luo S-D, Chen Y-J, Liu C-T, Rau K-M, Chen Y-C, Tsai H-T, et al. Osteopontin involves cisplatin resistance and poor prognosis in oral squamous cell carcinoma. Biomed Res Int. 2015;2015:1–13. doi:10.1155/2015/508587.

    Article  CAS  Google Scholar 

  • Machado JP, Johnson WE, O’Brien SJ, Vasconcelos V, Antunes A. Adaptive evolution of the matrix extracellular phosphoglycoprotein in mammals. BMC Evol Biol. 2011;11:342. doi:10.1186/1471-2148-11-342.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Mason CK, McFarlane S, Johnston PG, Crowe P, Erwin PJ, Domostoj MM, et al. Agelastatin A: a novel inhibitor of osteopontin-mediated adhesion, invasion, and colony formation. Mol Cancer Ther. 2008;7:548–58. doi:10.1158/1535-7163.mct-07-2251.

    Article  PubMed  CAS  Google Scholar 

  • Mazzali M, Kipari T, Ophascharoensuk V, Wesson JA, Johnson R, Hughes J. Osteopontin – a molecule for all seasons. QJM: Mon J Assoc Physicians. 2002;95:3–13.

    Article  CAS  Google Scholar 

  • Mi Z, Guo H, Russell MB, Liu Y, Sullenger BA, Kuo PC. RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. Mol Ther. 2008;17:153–61. doi:10.1038/mt.2008.235.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Mi Z, Guo H, Kuo PC. Identification of osteopontin-dependent signaling pathways in a mouse model of human breast cancer. BMC Res Notes. 2009;2:119. doi:10.1186/1756-0500-2-119.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Mitra A, Menezes ME, Pannell LK, Mulekar MS, Honkanen RE, Shevde LA, et al. DNAJB6 chaperones PP2A mediated dephosphorylation of GSK3beta to downregulate beta-catenin transcription target, osteopontin. Oncogene. 2012;31:4472–83. doi:10.1038/onc.2011.623.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Nemir M, Bhattacharyya D, Li X, Singh K, Mukherjee AB, Mukherjee BB. Targeted inhibition of osteopontin expression in the mammary gland causes abnormal morphogenesis and lactation deficiency. J Biol Chem. 2000;275:969–76.

    Article  CAS  PubMed  Google Scholar 

  • Ng L, Wan T, Chow A, Iyer D, Man J, Chen G, et al. Osteopontin overexpression induced tumor progression and chemoresistance to oxaliplatin through induction of stem-like properties in human colorectal cancer. Stem Cells Int. 2015;2015:1–8. doi:10.1155/2015/247892.

    Article  CAS  Google Scholar 

  • Oldberg A, Franzen A, Heinegard D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci U S A. 1986;83:8819–23.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Prince CW, Oosawa T, Butler WT, Tomana M, Bhown AS, Bhown M, et al. Isolation, characterization, and biosynthesis of a phosphorylated glycoprotein from rat bone. J Biol Chem. 1987;262:2900–7.

    PubMed  CAS  Google Scholar 

  • Sangaletti S, Tripodo C, Sandri S, Torselli I, Vitali C, Ratti C, et al. Osteopontin shapes immunosuppression in the metastatic Niche. Cancer Res. 2014;74:4706–19. doi:10.1158/0008-5472.can-13-3334.

    Article  PubMed  CAS  Google Scholar 

  • Schulze EB, Hedley BD, Goodale D, Postenka CO, Al-Katib W, Tuck AB, et al. The thrombin inhibitor Argatroban reduces breast cancer malignancy and metastasis via osteopontin-dependent and osteopontin-independent mechanisms. Breast Cancer Res Treat. 2008;112:243–54. doi:10.1007/s10549-007-9865-4.

    Article  PubMed  CAS  Google Scholar 

  • Senger DR, Wirth DF, Hynes RO. Transformation-specific secreted phosophoproteins. Nature. 1980;286:619–21.

    Article  PubMed  CAS  Google Scholar 

  • Shevde LA, Samant RS. Role of osteopontin in the pathophysiology of cancer. Matrix Biol. 2014;37:131–41. doi:10.1016/j.matbio.2014.03.001.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Shojaei F, Scott N, Kang X, Lappin PB, Fitzgerald AA, Karlicek S, et al. Osteopontin induces growth of metastatic tumors in a preclinical model of non-small lung cancer. J Exp Clin Cancer Res. 2012;31:26. doi:10.1186/1756-9966-31-26.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Smith JH, Denhardt DT. Molecular cloning of a tumor promoter-inducible mRNA found in JB6 mouse epidermal cells: induction is stable at high, but not at low, cell densities. J Cell Biochem. 1987;34:13–22. doi:10.1002/jcb.240340103.

    Article  PubMed  CAS  Google Scholar 

  • Sodek J, Ganss B, McKee MD. Osteopontin. Crit Rev Oral Biol Med: An Off Publ Am Assoc Oral Biologists. 2000;11:279–303.

    Article  CAS  Google Scholar 

  • Sun H, Zhu X, Lu PY, Rosato RR, Tan W, Zu Y. Oligonucleotide aptamers: new tools for targeted cancer therapy. Mol Ther: Nucleic Acids. 2014;3:e182. doi:10.1038/mtna.2014.32.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Talbot LJ, Mi Z, Bhattacharya SD, Kim V, Guo H, Kuo PC. Pharmacokinetic characterization of an RNA aptamer against osteopontin and demonstration of in vivo efficacy in reversing growth of human breast cancer cells. Surgery. 2011;150:224–30. doi:10.1016/j.surg.2011.05.015.

    Article  PubMed  Google Scholar 

  • Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347:1260419. doi:10.1126/science.1260419.

    Article  PubMed  CAS  Google Scholar 

  • Wang D, Yamamoto S, Hijiya N, Benveniste EN, Gladson CL. Transcriptional regulation of the human osteopontin promoter: functional analysis and DNA-protein interactions. Oncogene. 2000;19:5801–9. doi:10.1038/sj.onc.1203917.

    Article  PubMed  CAS  Google Scholar 

  • Weber GF. The cancer biomarker osteopontin: combination with other markers. Cancer Genomics Proteomics. 2011;8:263–88.

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

NIH R01CA194048 grant to R.S.S.

Author information

Authors and Affiliations

  1. Division of Molecular and Cellular Pathology, Department of Pathology, University of Alabama at Birmingham, Wallace Tumor Institute, 1824 6th Ave. S, Birmingham, AL, USA

    Swapnil Bawage, Shannon E. Weeks & Rajeev S. Samant

  2. Department of Pathology and Comprehensive Cancer Center, The University of Alabama, Birmingham, AL, USA

    Rajeev S. Samant

  3. Division of Molecular and Cellular Pathology, Department of Pathology and Comprehensive Cancer Center, University of Alabama at Birmingham, Wallace Tumor Institute, Birmingham, AL, USA

    Lalita A. Shevde

Authors
  1. Swapnil Bawage
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shannon E. Weeks
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lalita A. Shevde
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rajeev S. Samant
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rajeev S. Samant .

Editor information

Editors and Affiliations

  1. Department of Molecular Science and Technology, Ajou University, Suwon, Korea

    Sangdun Choi

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Bawage, S., Weeks, S.E., Shevde, L.A., Samant, R.S. (2018). Osteopontin (Spp1). In: Choi, S. (eds) Encyclopedia of Signaling Molecules. Springer, Cham. https://doi.org/10.1007/978-3-319-67199-4_101771

Download citation

Publish with us

Policies and ethics

Search

Navigation